Pilocarpine Hydrochloride Drug Due Diligence Report 2026

This Pilocarpine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

125

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Pilocarpine Hydrochloride can convert its Small molecule drug profile and mAChRs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pilocarpine Hydrochloride (query alias: pilocarpine)
Modality / target	Small molecule drug; mAChRs; mAChRs agonists
Highest global status	Approved
Originator	Alcon Canada, Inc.
Active developers	Sandoz, Inc., Romeg Therapeutics LLC, Boryung Corp.

The MCP disease footprint includes Presbyopia, Acute angle-closure glaucoma, Ocular Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2025/07/090630	Phase 4	Not Yet Recruiting	206	Not disclosed
NCT07113210	Phase 4	Recruiting	36	Near Visual Acuity Questionnaire-Presbyopia
CTR20261783	Phase 3	进行中（招募中）	1	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Multi-Center, Double-Masked, Vehicle-Controlled, Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Phase 3; n=178; evaluation: not stated. Reported fields: Number of Participants With Treatment Emergent Adverse Events. = 16 Participants ; -; Number of Participants With Treatment Emergent Adverse Events. = 43 Participants

Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia

Phase 3; n=333; evaluation: not stated. Reported fields: Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects: Odds Ratio (OR) = 2.27(95% CI, 1.23 - 4.20), P-Value = <0.01; Odds Ratio (OR) = 1.44(95% CI); Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects = 27 Participants ; Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated Subjects = 22 Participants

COMMON SYSTEMIC INVOLVEMENT AND WORSENING DISEASE BURDEN IN PATIENTS WITH SJÖGREN’S DISEASE: DATA FROM PORTRESS, THE PORTUGUESE REGISTRY OF SJÖGREN’S DISEASE

Not Applicable; n=1375; evaluation: Negative. Reported fields: Disease activity worsening = 24 % ; Disease activity worsening = 24 % ; Disease activity worsening = 24 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pilocarpine Hydrochloride addresses Presbyopia, Acute angle-closure glaucoma, Ocular Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-10-16	Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea	Approved	US$18.0M stated total
2021-09-17	极目生物宣布拓展与Eyenovia公司合作协议，新增扩瞳药物MydCombi™（ARVN004）	NDA/BLA	Financial terms not disclosed
2020-08-10	Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea	Not disclosed	US$45.8M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Synthesis method and purification method of pilocarpine”. The milestone feed surfaced a patent-application signal described as “Intermediate compounds of pilocarpine and preparation method therefor”. The milestone feed surfaced a patent-application signal described as “Ophthalmic composition comprising pilocarpine and a redness reduction agent”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO